Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction

Journal of Allergy and Clinical Immunology

Volumn 102, Issue 6 II, 1998, Pages 935-942

  Nathan, Robert A ^a,n   Bernstein, Jonathan A ^b   Bielory, Leonard ^c   Bonuccelli, Catherine M ^d   Calhoun, William J ^e   Galant, Stanley P ^f   Hanby, Laura A ^d   Kemp, James P ^g   Kylstra, Jelle W ^d   Nayak, Anjuli S ^h   O'Connor, John P ⁱ   Schwartz, Howard J ^j   Loren Southern, D ^k   Spector, Sheldon L ^l   Williams, Paul V ^m  

^a Asthma and Allergy PC and Research Center   (United States)

^b Bernstein Clinical Research Center   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d Zeneca Pharmaceuticals   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f Asthma and Allergy Research Center

^g ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^h Asthma and Allergy Research Associates Inc   (United States)

ⁱ THOMAS JEFFERSON UNIVERSITY   (United States)

^j UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^k Princeton Allergy and Asthma Associates   (United States)

^l Allergy Research Foundation   (United States)

^m Northwest Asthma & Allergy Center   (United States)

ⁿ Asthma & Allergy Associates PC and Research Center   (United States)

more..

Author keywords

Asthma; Leukotriene receptor antagonist; Nasal congestion; Number needed to treat, peripheral blood eosinophils; Pulmonary function; Quality of life; Reversible airflow obstruction; Zafirlukast

Indexed keywords

ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PLACEBO; SALBUTAMOL; ZAFIRLUKAST;

ADOLESCENT; ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL; FEMALE; HEADACHE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHARYNGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

EID: 0032430610     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0091-6749(98)70331-8     Document Type: Article

References (22)

1. 4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219. Clin Pharmacol Ther 1993;54:430-6.
2. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994;150:618-23.
3. Fish JE, Kemp JP, Lockey RF, Glass M, Hanby LA, Bonuccelli CM, et al. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. Clin Ther 1997;19:675-90.
4. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Killer TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992;47:76-83.
5. Israel E, Cohn J, Dubé L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial. JAMA 1996;275:931-6.
6. Juniper EF, Johnston PR, Borkhoff CM, Guyatt GH, Boulet L-P, Haukioja A. Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol. Am J Respir Crit Care Med 1995;151:66-70.
7. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995;152:1107-36.
8. Brown HK, Kempton RA. The application of REML in clinical trials. Stat Med 1994;13:1601-17.
9. Juniper EF, Guyatt GH, Will an A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994;47:81-7.
10. 4-receptor antagonist, ICI 204,219 relieved symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 1995;151:1734-9.
11. Knapp HR. Reduced allergen-induced nasal congestion in leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med 1990;323:1745-8.
12. Henderson WR Jr. Role of leukotrienes in asthma. Ann Allergy 1994;72:272-8.
13. 4 in allergic rhinitis. Ann Allergy 1988;60:537-40.
14. Lydick E, Epstein RS. Interpretation of quality of life changes. Qual Life Res 1993;2:221-6.
15. Juniper EJ. Quality of life questionnaires: Does statistically significant = clinically important? J Allergy Clin Immunol 1998;102:16-7.
16. Reiss TF, Chervinsky P, Dockhorn R, Shingo S, Seidenberg B, Edwards TB, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch Intern Med 1998;158:1213-20.
17. Guyatt GH, Juniper EF, Walter SD, Griffith LE, Goldstein RS. Interpreting treatment effects in randomised trials. Br Med J 1998;316:690-3.
18. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997;126:712-20.
19. 4 receptor antagonist, pranlukast, or an interleukin-5 monoclonal antibody. Am J Respir Crit Care Med 1996;154:850-7.
20. Muñoz NM, Douglas I, Mayer D, Herrnreiter A, Zhu X, Leff AR. Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism. Am J Respir Crit Care Med 1997;155:1398-403.
21. Ulrik CS. Peripheral eosinophil counts as a marker of disease activity in intrinsic and extrinsic asthma. Clin Exp Allergy 1995;25:820-7.
22. National Asthma Education Prevention Program. Expert Panel Report II: Guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health; 1997. NIH Publication No: 97-4051.